FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape

Area of Science:

• Oncology
• Genitourinary Cancer
• Translational Research

Background:

• Advanced urothelial cancer (UC) treatment is evolving, with optimal sequencing of therapies after initial treatment remaining a challenge.
• Fibroblast growth factor receptor (FGFR) alterations are key drivers in a subset of advanced UC, making them a target for precision medicine.

Purpose of the Study:

• To compare the efficacy of erdafitinib versus chemotherapy or immunotherapy in patients with advanced UC harboring FGFR3/2 alterations.
• To provide data that informs subsequent treatment strategies in advanced urothelial cancer.

Main Methods:

• Phase 3 clinical trial design.
• Inclusion of patients with advanced urothelial cancer and specific FGFR3/2 alterations.
• Comparison of erdafitinib efficacy against standard chemotherapy or immunotherapy regimens.

Main Results:

• The THOR trial provides valuable data on the efficacy of erdafitinib in this specific patient population.
• Results inform the potential role of erdafitinib in the treatment landscape of advanced UC.
• Data highlights the importance of molecular profiling for treatment selection.

Conclusions:

• The study offers insights into sequencing strategies for advanced urothelial cancer.
• Molecular testing for FGFR3/2 alterations is crucial for identifying eligible patients.
• Findings contribute to the evolving management of advanced UC.